Cargando…

Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report

INTRODUCTION: The follicular variant of papillary thyroid cancer (FVPTC) can be noninvasive or invasive. The invasive form of FVPTC commonly harbors BRAF mutations whereas RAS mutations are more often associated with noninvasive FVPTC and a favorable clinical outcome. CASE REPORT: A 47-year-old man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehrzad, Raman, Nishino, Michiya, Nucera, Carmelo, Dias-Santagata, Dora, Hennessey, James V., Hasselgren, Per-Olof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547242/ https://www.ncbi.nlm.nih.gov/pubmed/28780248 http://dx.doi.org/10.1016/j.ijscr.2017.06.067

Ejemplares similares

Transcriptome of melanoma cells from two mouse models, Tyr:NRas(Q61K)and Tyr:Rack1-HA, Tyr:NRas(Q61K)
por: Campagne, Cécil, et al.
Publicado: (2017)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Papillary thyroid cancer with extrathyroidal extension of desmoid-type fibromatosis. A case report of an aggressive presentation of an uncommon pathologic entity
por: Roth, Eve M., et al.
Publicado: (2019)

Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response
por: Lu, Jin-Ying, et al.
Publicado: (2016)

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2017)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy
por: McGrail, Kimberley, et al.
Publicado: (2022)

P858: FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION
por: Liotti, Romano, et al.
Publicado: (2023)

Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies
por: Vujic, Igor, et al.
Publicado: (2014)

Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach
por: Jiang, Wei, et al.
Publicado: (2014)

NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2015)

Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation
por: McReynolds, Lisa J., et al.
Publicado: (2019)

Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid
por: Bae, Ja-Seong, et al.
Publicado: (2014)

Deregulated Nras Expression in Knock-In Animals Harboring a Gammaretroviral Long Terminal Repeat at the Nras/Csde1 Locus
por: Ballarín-González, Borja, et al.
Publicado: (2013)

NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications
por: Angelino, Giulia, et al.
Publicado: (2016)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Liquid Biopsy with Detection of NRAS(Q61K) Mutation in Cerebrospinal Fluid: An Alternative Tool for the Diagnosis of Primary Pediatric Leptomeningeal Melanoma
por: Mastronuzzi, Angela, et al.
Publicado: (2022)

ODP465 BRAF V600 and NRAS Q61 mutations in thyroid fine-needle aspiration (FNA) with indeterminate cytology in Argentina
por: Repetto, Esteban M, et al.
Publicado: (2022)

Activated Mutant NRas(Q61K) Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism
por: Li, Ang, et al.
Publicado: (2012)

Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS
por: Kinsler, Veronica A, et al.
Publicado: (2013)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)

Cytomorphology of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and the Impact of New Nomenclature on Molecular Testing
por: Shrestha, Rupendra T., et al.
Publicado: (2019)

The Smallpox Epidemics in America in the 1700s and the Role of the Surgeons: Lessons to be Learned During the Global Outbreak of COVID-19
por: Hasselgren, Per-Olof
Publicado: (2020)

Deciphering Conformational Changes of the GDP-Bound NRAS Induced by Mutations G13D, Q61R, and C118S through Gaussian Accelerated Molecular Dynamic Simulations
por: Yu, Zhiping, et al.
Publicado: (2022)

NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
por: Yu, Ryan Timothy D., et al.
Publicado: (2020)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody
por: Gui, Lin, et al.
Publicado: (2023)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023)

Comment on Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats
por: Alamdari, Nima, et al.
Publicado: (2012)

Unmasking the Silent Invader: A Rare Case of Follicular Thyroid Carcinoma With Skull Metastasis and an Uncommon KRAS Q61R Mutation
por: Huang, Hehua (Hannah), et al.
Publicado: (2023)

El año 61
por: Alonso, Dora 1910-
Publicado: (1981)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Proteomic profiling of follicular and papillary thyroid tumors
por: Sofiadis, Anastasios, et al.
Publicado: (2012)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
por: Shackelford, Rodney, et al.
Publicado: (2014)

Branchial Cleft Cyst Harbors Metastatic Papillary Thyroid Carcinoma
por: Marotta, Dario A, et al.
Publicado: (2021)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions
por: Chuang, Hao-Wen, et al.
Publicado: (2021)

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model
por: Duquette, Mark, et al.
Publicado: (2015)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bquu9l55giqmrcfeecjjdkm6av